This clinical trial is focused on providing continued access to treatment for patients with a neurological disease. The study involves the use of a medication called Ocrelizumab, which is administered as a concentrate for solution for infusion or as a solution for injection. The purpose of the study is to ensure that patients who were previously enrolled in a related study can continue receiving their treatment if they do not have access to it locally.

In addition to Ocrelizumab, the study also involves other medications, including Lidocaine Hydrochloride Monohydrate, Methylprednisolone Acetate, and Dexamethasone Acetate. These medications are used in various forms, such as oral, intravenous, and subcutaneous routes, to support the treatment of the neurological condition. The study does not provide new treatments but continues the existing therapy for those who have been benefiting from it.

Participants in this study will continue their treatment over a period of time, ensuring they receive the necessary care without interruption. The study is designed to be an extension of previous research, allowing patients to maintain their health and manage their condition effectively. The trial aims to provide a seamless transition for patients who are already on these therapies, ensuring they have ongoing access to their medication.